The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.

Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.

Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.